Storys aus Mechelen, Belgium And Lausanne, Switzerland

05.11.2013 – 11:02
Biocartis
Biocartis Poised for 2014 Commerical Launch with EUR 30 Million Series E Equity Fundraising
Mechelen, Belgium And Lausanne, Switzerland (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, easy to use platforms and clinically relevant assays, announced today the completion of an EUR 30 million Series E equity fundraising. The additional capital will be ...
mehr
22.10.2013 – 23:05
Biocartis
Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
Mechelen, Belgium And Lausanne, Switzerland (ots/PRNewswire) - Biocartis also introduces IdyllaTM, the brand name for its innovative and high-quality diagnostic platform (previously codenamed Apollo). IdyllaTM is designed to carry out fast and accurate analysis of a broad range of clinical samples[1]. The platform ...
mehr